000112016 001__ 112016 000112016 005__ 20240319080949.0 000112016 0247_ $$2doi$$a10.3390/cancers14061589 000112016 0248_ $$2sideral$$a127961 000112016 037__ $$aART-2022-127961 000112016 041__ $$aeng 000112016 100__ $$aMorote, J. 000112016 245__ $$aThe Barcelona Predictive Model of Clinically Significant Prostate Cancer 000112016 260__ $$c2022 000112016 5060_ $$aAccess copy available to the general public$$fUnrestricted 000112016 5203_ $$aA new and externally validated MRI-PM for csPCa was developed in the metropolitan area of Barcelona, and a web-RC designed with the new option of selecting the csPCa probability threshold. The development cohort comprised 1486 men scheduled to undergo a 3-tesla multiparametric MRI (mpMRI) and guided and/or systematic biopsies in one academic institution of Barcelona. The external validation cohort comprised 946 men in whom the same diagnostic approach was carried out as in the development cohort, in two other academic institutions of the same metropolitan area. CsPCa was detected in 36.9% of men in the development cohort and 40.8% in the external validation cohort (p = 0.054). The area under the curve of mpMRI increased from 0.842 to 0.897 in the developed MRI-PM (p < 0.001), and from 0.743 to 0.858 in the external validation cohort (p < 0.001). A selected 15% threshold avoided 40.1% of prostate biopsies and missed 5.4% of the 36.9% csPCa detected in the development cohort. In men with PI-RADS <3, 4.3% would be biopsied and 32.3% of all existing 4.2% of csPCa would be detected. In men with PI-RADS 3, 62% of prostate biopsies would be avoided and 28% of all existing 12.4% of csPCa would be undetected. In men with PI-RADS 4, 4% of prostate biopsies would be avoided and 0.6% of all existing 43.1% of csPCa would be undetected. In men with PI-RADS 5, 0.6% of prostate biopsies would be avoided and none of the existing 42.0% of csPCa would be undetected. The Barcelona MRI-PM presented good performance on the overall population; however, its clinical usefulness varied regarding the PI-RADS category. The selection of csPCa probability thresholds in the designed RC may facilitate external validation and outperformance of MRI-PMs in specific PI-RADS categories. 000112016 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/PI20/01666 000112016 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000112016 590__ $$a5.2$$b2022 000112016 592__ $$a1.312$$b2022 000112016 591__ $$aONCOLOGY$$b72 / 241 = 0.299$$c2022$$dQ2$$eT1 000112016 593__ $$aOncology$$c2022$$dQ1 000112016 593__ $$aCancer Research$$c2022$$dQ2 000112016 594__ $$a7.4$$b2022 000112016 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000112016 700__ $$0(orcid)0000-0003-0178-4567$$aBorque-Fernando, A.$$uUniversidad de Zaragoza 000112016 700__ $$aTriquell, M. 000112016 700__ $$aCelma, A. 000112016 700__ $$aRegis, L. 000112016 700__ $$aEscobar, M. 000112016 700__ $$aMast, R. 000112016 700__ $$ade Torres, I.M. 000112016 700__ $$aSemidey, M.E. 000112016 700__ $$aAbascal, J.M. 000112016 700__ $$aSola, C. 000112016 700__ $$aServian, P. 000112016 700__ $$aSalvador, D. 000112016 700__ $$aSantamaría, A. 000112016 700__ $$aPlanas, J. 000112016 700__ $$0(orcid)0000-0002-3007-302X$$aEsteban Escaño, L.M. 000112016 700__ $$aTrilla, E. 000112016 7102_ $$11013$$2817$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Urología 000112016 773__ $$g14, 6 (2022), 1589 [13 pp.]$$pCancers$$tCancers$$x2072-6694 000112016 8564_ $$s1736121$$uhttps://zaguan.unizar.es/record/112016/files/texto_completo.pdf$$yVersión publicada 000112016 8564_ $$s2842820$$uhttps://zaguan.unizar.es/record/112016/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000112016 909CO $$ooai:zaguan.unizar.es:112016$$particulos$$pdriver 000112016 951__ $$a2024-03-18-12:53:59 000112016 980__ $$aARTICLE